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Vascular Medicine
Vascular Effects of Apelin In Vivo in Man
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Ewan B. Goudie, BSC,* Neil R. Johnston, MSC,* Sushma Sharma, PHD,† Ilene Neilson, BSC,†
David J. Webb, MD, FRCP,* Ian L. Megson, PHD,† Andrew D. Flapan, MD, MRCP,‡
David E. Newby, PHD, FRCP*
Edinburgh and Inverness, United Kingdom
Objectives This study was designed to establish the direct vascular effects of apelin in vivo in man.
Background Apelin is the endogenous ligand for the previously orphaned G-protein–coupled receptor, APJ. This novel pathway
is widely expressed in the cardiovascular system and is emerging as an important mediator of cardiovascular
homeostasis. In pre-clinical models, apelin causes venous and arterial vasodilation.
Methods Vascular effects of apelin were assessed in 24 healthy volunteers. Dorsal hand vein diameter was measured by
the Aellig technique during local intravenous infusions (0.1 to 3 nmol/min) of apelin-36, (Pyr1)apelin-13, and
sodium nitroprusside (0.6 nmol/min). Forearm blood flow was measured by venous occlusion plethysmography
during intrabrachial infusions of apelin-36 and (Pyr1)apelin-13 (0.1 to 30 nmol/min) and subsequently in the
presence or absence of a “nitric oxide clamp” (nitric oxide synthase inhibitor, L-NG-monomethylarginine [8 mol/
min], coinfused with nitric oxide donor, sodium nitroprusside [90 to 900 ng/min]), or a single oral dose of aspi-
rin (600 mg) or matched placebo.
Results Although sodium nitroprusside caused venodilation (p  0.0001), apelin-36 and (Pyr1)apelin-13 had no effect on
dorsal hand vein diameter (p  0.2). Both apelin isoforms caused reproducible vasodilation in forearm resis-
tance vessels (p  0.0001). (Pyr1)apelin-13–mediated vasodilation was attenuated by the nitric oxide clamp
(p  0.004) but unaffected by aspirin (p  0.7).
Conclusions Although having no apparent effect on venous tone, apelin causes nitric oxide–dependent arterial vasodilation in
vivo in man. The apelin-APJ system merits further clinical investigation to determine its role in cardiovascular
homeostasis. (J Am Coll Cardiol 2008;52:908–13) © 2008 by the American College of Cardiology Foundation
Apelin is the endogenous ligand for the orphan G-protein–
coupled receptor, APJ (1,2). The full-length mature pep-
tide, apelin-36, comprises 36 amino acids but the most
potent isoform is the pyroglutamated form of apelin-13,
(Pyr1)apelin-13 (2–4). The APJ receptors are present on
endothelial cells, vascular smooth muscle cells, and cardio-
myocytes (5).
In rodent models, exogenous apelin administration causes a
rapid nitric oxide (NO)-dependent fall in blood pressure and
mean capillary filling pressure, indicating powerful vasodilator
and venodilator effects (3). In ex vivo myography studies, apelin
causes NO-dependent vasorelaxation in human mesenteric
arteries (6) and venoconstriction in endothelium-denuded
human saphenous veins (7). As a first step toward character-
izing the in vivo cardiovascular profile of apelin in man, we
sought to determine its direct vasomotor effects in the periph-
eral venous and arterial circulation.
Methods
Subjects. Twenty-four healthy male volunteers (age 19 to
24 years) participated following written informed consent,
with the approval of the local research ethics committee,
and in accordance with the Declaration of Helsinki. Partic-
ipants were not taking regular medication and abstained
from alcohol for 24 h and from food and caffeine-containing
drinks for at least 4 h before studies.
Vascular studies. Studies were conducted in a quiet
temperature-controlled room (22°C to 25°C). Heart rate and
blood pressure were monitored at regular intervals with a
semiautomated, oscillometric sphygmomanometer (HEM
705CP, Omron, Tokyo, Japan).
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VENOUS STUDIES. Intravenous infusions (0.25 ml/min)
were administered through a 23-gauge needle in a non-
branching dorsal hand vein (DHV). Venous tone was
measured by the Aellig technique during norepinephrine
(Hospira, Illinois; 1 to 32 ng/min) preconstriction (50% to
70% reduction in diameter) as described previously (8). Six
subjects (Fig. 1, protocol 1) received incremental infusions
of (Pyr1)apelin-13 or apelin-36 (Clinalfa AG, Läufelfingen,
Switzerland; 0.1 to 3 nmol/min) followed, after saline
washout, by a single dose of sodium nitroprusside (SNP)
(Mayne Pharma Plc, Warwickshire, United Kingdom)
at 0.6 nmol/min. A further 3 subjects received
(Pyr1)apelin-13 and apelin-36 in the absence of norepi-
nephrine preconstriction.
ARTERIAL STUDIES. Intra-arterial infusions (1 ml/min)
were administered through a 27-standard-wire-gauge steel
brachial artery needle. Forearm blood flow (FBF) was
measured in both forearms by venous occlusion plethysmog-
raphy as described previously (9,10). In protocol 2A, blood
samples (10 ml) were drawn from each arm into ethyl-
enediaminetetraacetic acid and centrifuged to obtain plasma
that was stored at 80°C. Plasma apelin concentrations were
measured using a commercially available enzyme-linked im-
munosorbant assay (Phoenix Pharmaceuticals Inc., Burlin-
game, California.). In protocol 3, a “NO clamp” (L-NG-
monomethylarginine [8 mol/
min] coinfused with SNP [90 to
900 ng/min]) was used to allow
simulation of normal basal NO
activity during complete inhibition
of endogenous NO synthesis, as
described previously (11). Dispers-
ible aspirin (600 mg; Aspar Phar-
maceuticals Ltd., London, United
Kingdom) was administered orally
30 min before study commence-
ment to inhibit production of
prostaglandins (12).
Eight subjects attended on 4
occasions at least 1 week apart to receive incremental
infusions of apelin-36 or (Pyr1)apelin-13 (0.1 to 30
nmol/min) in the presence and absence of saline wash-
outs (protocol 2). A further 8 subjects attended on 4
occasions to receive, in a randomized order: 1) the NO
clamp and oral aspirin; 2) the NO clamp and oral
placebo; 3) saline placebo and oral aspirin; and 4) saline
placebo and oral placebo, followed on all occasions by
sequential infusions of (Pyr1)apelin-13 (0.3 to 3 nmol/
min) and acetylcholine (Novartis AG, Basel, Switzerland;
5 to 20 g/min) in a double-blind manner (protocol 3).
Abbreviations
and Acronyms
ANOVA  analysis of
variance
APJ  apelin receptor
AUC  area under the
curve
DHV  dorsal hand vein
FBF  forearm blood flow
NO  nitric oxide
SNP  sodium
nitroprusside
Figure 1 Study Design
Protocol 1: Dorsal hand vein infusions of (Pyr1)apelin-13 or apelin-36 (blue; nmol/min), sodium nitroprusside (SNP) (red; nmol/min) and saline, with coinfusion of norepi-
nephrine. Protocol 2 (A and B): Intrabrachial infusions of (Pyr1)apelin-13 or apelin-36 (blue; nmol/min) and saline with venous blood sampling (1). Protocol 3: Intrabra-
chial infusions of (Pyr1)apelin-13 (blue; nmol/min) and acetylcholine (yellow; g/min) with coadministration of aspirin or placebo, and “nitric oxide clamp” or saline
placebo. L-NMMA  L-NG-monomethylarginine.
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Data and statistical analyses. The DHV (13) and FBF
(9) data were analyzed as described previously. The
effects of the NO clamp and aspirin on FBF responses
to (Pyr1)apelin-13 and acetylcholine were assessed by
calculating area under the curve (AUC) using the trape-
zoid method. Apelin concentrations were logarith-
mically transformed prior to analysis. Variables are
reported as mean  standard error of mean and
analyzed using repeated-measures analysis of variance
(ANOVA) with post-hoc Bonferroni corrections, regres-
sion analysis, and 2-tailed Student t test as appropriate
(Graph-Pad Prism, GraphPad Software, Inc., San Diego,
California). Statistical significance was taken at the 5%
level.
Figure 2 DHV Diameter During Coinfusion of Norepinephrine
DHV diameter during coinfusion of norepinephrine and (A) incremental doses of (Pyr1)apelin-13 (solid squares) and single dose of SNP (solid diamonds; 0.6 nmol/min)
and (B) incremental doses of apelin-36 (open squares) and single dose of SNP (open diamonds; 0.6 nmol/min). ***p  0.001, paired Student t test. DHV  dorsal
hand vein; other abbreviations as in Figure 1.
Figure 3 Infused FBF
Infused FBF (A) in protocol 2A during infusion of (Pyr1)apelin-13 (top, solid squares; 1-way ANOVA) and apelin-36 (bottom, open squares; 1-way ANOVA) and (B) during
incremental infusion of (Pyr1)apelin-13 (solid squares) versus apelin-36 (open squares); 2-way ANOVA with repeated measures. *p  0.05, **p  0.01, ***p  0.001,
post-hoc Bonferroni tests. ANOVA  analysis of variance; FBF  forearm blood flow.
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Results
In all studies, apelin infusions were well tolerated with no
serious adverse events. There were no changes in heart rate
or blood pressure.
Neither (Pyr1)apelin-13 nor apelin-36 caused venoconstric-
tion in relaxed DHVs (data not shown). Following precon-
striction, DHV diameter was unaffected by (Pyr1)apelin-13
(p  0.18, 1-way ANOVA) or apelin-36 (p  0.24, 1-way
ANOVA) but increased by SNP (p  0.0001) (Fig. 2).
(Pyr1)apelin-13 and apelin-36 increased FBF in the
infused arm (p  0.001) (Figs. 3 and 4). Vasodilation to
apelin-36 was dose-dependent (r2  0.41, p  0.0001) but
plateaued rapidly with (Pyr1)apelin-13 (r2  0.003, p 
0.73). After continuous dose escalation of each apelin
isoform, FBF declined gradually over 42 min (for both: p 
0.0001, ANOVA). With apelin-36, FBF remained elevated
during saline washout (p 0.0001) and failed to rise further
during subsequent reinfusion (Fig. 3). With (Pyr1)apelin-13,
FBF remained elevated at 6 min during saline washout (p 
0.05) but not thereafter, and further vasodilation was demon-
strable during subsequent reinfusion (p  0.0001) (Fig. 3).
At the highest dose of 30 nmol/min, infused FBF was
greater with apelin-36 compared with (Pyr1)apelin-13
(p  0.05) (Fig. 3B). The inclusion of saline washouts
between doses did not affect vasodilation to either
(Pyr1)apelin-13 (p  0.68) (Fig. 4B) or apelin-36 (p 
0.93) (Fig. 4C). With both apelin isoforms, FBF increased
in the noninfused arm (p 0.0001, ANOVA) at 30 nmol/min
(p  0.05, post-hoc Bonferroni tests; data not shown).
Plasma apelin concentrations in the infused arm rose with
increasing doses of apelin-36 (p  0.0001) (Fig. 5) and
increased in the noninfused arm from 10 nmol/min (p 0.01).
L-NG-monomethylarginine reduced infused FBF (3.48 
0.41 ml/100 ml/min to 2.10  0.17 ml/100 ml/min; p 
Figure 4 Infused FBF
Infused FBF (A) in protocol 2B during infusion of (Pyr1)apelin-13 (top, solid squares; 1-way ANOVA) and apelin-36 (bottom, open squares; 1-way ANOVA) and during incre-
mental infusion of (Pyr1)apelin-13 (B) and apelin-36 (C) in the presence (solid squares) and absence (open squares) of saline washouts (for both: p  0.05, 2-way
ANOVA with repeated measures). **p  0.01, ***p  0.001, post-hoc Bonferroni tests. Abbreviations as in Figure 3.
Figure 5 Plasma Apelin Concentration
Plasma apelin concentration in venous blood samples from infused (solid
bars) and noninfused arm (open bars) during intrabrachial apelin-36 infusion.
**p  0.01, ***p  0.001, 1-way ANOVA with post-hoc Bonferroni tests.
Abbreviation as in Figure 3.
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0.001) but this was restored with SNP coinfusion (3.20
 0.33 ml/100 ml/min; p  0.05 vs. baseline). Both
(Pyr1)apelin-13 (p  0.001) and acetylcholine (p  0.001)
increased infused FBF (Fig. 6). Coinfusion of the NO
clamp inhibited the response to (Pyr1)apelin-13 (AUC: 4.7
 0.9 AU vs. 1.7  0.7 AU; p  0.004) and acetylcholine
(AUC: 12.8  2.3 AU vs. 6.4  1.5 AU; p  0.02) but
aspirin had no effect (p  0.05 for both) (Fig. 6).
Discussion
This is the first study to examine the in vivo vascular actions of
apelin in man. Using robust well-validated techniques, we have
assessed the direct effects of 2 endogenous apelin isoforms on
vascular tone. Although not affecting peripheral venous tone,
apelin peptides cause vasodilation in peripheral resistance
vessels through a NO-dependent mechanism.
Effects of apelin on peripheral arteriolar tone. In keeping
with pre-clinical models and studies of human mesenteric
vessels in vitro, we have demonstrated that apelin causes
reproducible vasodilation in human forearm resistance vessels
in vivo. We studied 2 different apelin isoforms, apelin-36 and
(Pyr1)apelin-13, and both caused a rapid onset of vasodilation.
Apelin-36 exhibited a slower offset, with vasodilation persist-
ing for at least 42 min after cessation of infusion. This
prolonged offset of action is unusual but has been described
with other agonists, such as the V2 agonist, desmopressin (14).
It is consistent with in vitro data showing that apelin-36
exhibits a much slower dissociation from the APJ receptor than
(Pyr1)apelin-13 and causes prolonged biological activity in
microphysiometric assays (4). In addition, apelin appears to be
rapidly cleared from the circulation with a short plasma
half-life of no longer than 8 min. Although shorter apelin
peptides have more potent depressor activity in rats (15), we
saw no difference in potency between the 2 isoforms and a
greater response to apelin-36 at the highest dose. This was due,
at least in part, to a plateauing of the response to
(Pyr1)apelin-13 at higher doses that may have resulted from
APJ receptor internalization (16) combined with a shorter
duration of receptor activation.
Vasodilation to (Pyr1)apelin-13 was attenuated by two-
thirds during the NO clamp, indicating that vasodilation to
apelin is mediated predominantly by endothelial NO genera-
tion. As expected, the NO clamp also inhibited acetylcholine-
mediated vasodilation, which is known to be partly mediated
by NO (17). In contrast, systemic inhibition of prostanoid
generation with oral aspirin did not alter vasodilation to either
(Pyr1)apelin-13 or acetylcholine, alone or in combination with
the NO clamp. The dose of aspirin used in this study inhibits
bradykinin-induced endothelial production of prostacyclin by
at least 85% (12), suggesting that prostanoids do not provide a
major contribution to apelin-mediated vasodilation. Our in
vivo findings are in close agreement with Salcedo et al. (6) who
Figure 6 Infused FBF in Subjects During Infusion
Infused FBF in subjects during infusion of (top row) (Pyr1)apelin-13 in the presence (solid squares) or absence (open squares) of nitric oxide (NO) clamp (left) or aspirin
(right) and (bottom row) acetylcholine in the presence (solid circles) or absence (open circles) of NO clamp (left) or aspirin (right). p  0.0001; 1-way ANOVA for
dose responses to (Pyr1)apelin-13 and acetylcholine alone. For placebo versus NO clamp (AUC): (Pyr1)apelin-13, p  0.01; acetylcholine, p  0.05. For placebo versus
aspirin (AUC): (Pyr1)apelin-13, p  0.7; acetylcholine, p  0.9. AUC  area under the curve; other abbreviations as in Figure 3.
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recently demonstrated that NO synthase, but not cyclooxygen-
ase, inhibition attenuated relaxation to apelin in human mes-
enteric arteries in vitro.
Effects of apelin on peripheral venous tone. We demon-
strated constrictor and dilator responses to norepinephrine
and SNP, respectively, and employed doses of apelin 10-
fold higher than those required to cause vasodilation in the
forearm arterial circulation. It is unlikely therefore that the
lack of venous response to apelin reflected either inadequate
dosing or sensitivity of the technique. However, we exam-
ined the effects of apelin in a single peripheral venous bed
and cannot exclude the possibility of a direct effect on
central capacitance veins. Further clinical studies are re-
quired to determine the in vivo effects of apelin in specific
venous beds and on overall systemic venous tone.
Study limitations. We measured changes in FBF and
plasma apelin concentrations during local intrabrachial apelin
infusions. At infusion rates3 nmol/min, we detected a rise in
plasma apelin concentrations accompanied by an increase in
FBF in the noninfused arm, indicating spillover of infused
apelin into the systemic circulation. This spillover limits
interpretation of blood flow changes at the higher doses of
apelin because of potential concomitant effects on myocardial
contractility or activation of neurohumoral reflexes. However,
at apelin doses 3 nmol/min, changes in blood flow can be
solely ascribed to direct local vascular effects.
We have described the effects of exogenous apelin on
resistance vessels in the forearm vascular bed. Although con-
cordance between vasomotor responses in the forearm and
other vascular beds is generally good (18), differences do exist
and further studies will be needed to confirm our findings in
other vascular beds such as the coronary circulation.
Conclusions
We have shown that acute apelin administration in vivo in man
causes NO-mediated arterial vasodilation but does not appear
to affect peripheral venous tone. Increasing evidence from
pre-clinical models has suggested that apelin-APJ signaling
mediates important effects on cardiovascular homeostasis. Our
findings provide the strongest evidence to date of a role for the
apelin-APJ system in human cardiovascular regulation.
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